Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
A Utah judge has ordered the release of a transcript from a closed-door hearing in October over whether the man charged with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback